The polarization is assessed by flow cytofluorimetry and cytokine production.

The CD8 T cells become evaluated on their cytokine secretion, cytotoxicity and % of antigen specific T cells.

Cytokine accumulation is evaluated in the supernatants at 24h by ELISA, according to a standard protocol and it is measured at 450nm.

Treatment induced T cell responses will be evaluated by flow cytometry based methods (T cell phenotype, proliferation, perforin degranulation) and cytokine detection (Elispot, Elisa). The patients will be monitored for safety and toxicity of the treatment and for clinical response to immunotherapy.

Survival of yeast cells, spores or hyphae after uptake is reported as percentage of colony forming units after 3 days relative to the total number of cells growing in the absence of DCs exposure.

Absorbance is measured using a microplate reader at 620 nm.

Before injection all cell products will be thoroughly tested to exclude contamination and presence of viable tumor cells.